Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases

Stock Information for Seres Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Seres Therapeutics Inc.

Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates
Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst(TM) Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy
Seres Therapeutics to Participate in Piper Sandler Healthcare Conference
Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025
Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155
Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.